Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions

Metastatic or Recurrent Gastric Adenocarcinoma

Interventions

DRUG

Envafolimab

300mg,sc,d1,Q3W

DRUG

Oxaliplatin

130mg/m2, iv,d1,Q3W

DRUG

40mg/m2, op,bid,d1-14,Q3W

Trial Locations (1)

RECRUITING

Jiangsu Cancer Institute & Hospital, Nanjing

All Listed Sponsors

collaborator

Zhangjiagang First People's Hospital

OTHER

lead

Liangjun Zhu M.M.

OTHER